BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch

Reuters

2025/09/08

BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch

BioMarin Pharmaceutical Inc. has announced new data from multiple studies highlighting its ongoing research in bone health. At the American Society for Bone and Mineral Research 2025 Annual Meeting in Seattle, BioMarin presented results from 14 studies, including those concerning VOXZOGO® (vosoritide). The data demonstrated that treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children with achondroplasia and showed continued efficacy in children who received the medicine after the onset of puberty. Additionally, BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for ENPP1 deficiency. The initial pivotal data readout for the ENERGY 3 study in children with ENPP1 deficiency is expected in the first half of 2026, with a potential market launch in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66730) on September 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565846816"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565846816\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565846816?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565846816","market":"us","top_or_hot":-1,"title":"BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioMarin Pharmaceutical Inc. has announced new data from multiple studies highlighting its ongoing research in bone health. At the American Society for Bone and Mineral Research 2025 Annual Meeting in Seattle, BioMarin presented results from 14 studies, including those concerning VOXZOGO® (vosoritide). The data demonstrated that treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children with achondroplasia and showed continued efficacy in children who received the medicine after the onset of puberty. Additionally, BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for ENPP1 deficiency. The initial pivotal data readout for the ENERGY 3 study in children with ENPP1 deficiency is expected in the first half of 2026, with a potential market launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66730) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-08 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioMarin Pharmaceutical Inc. has announced new data from multiple studies highlighting its ongoing research in bone health. At the American Society for Bone and Mineral Research 2025 Annual Meeting in Seattle, BioMarin presented results from 14 studies, including those concerning VOXZOGO® (vosoritide). The data demonstrated that treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children with achondroplasia and showed continued efficacy in children who received the medicine after the onset of puberty. Additionally, BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for ENPP1 deficiency. The initial pivotal data readout for the ENERGY 3 study in children with ENPP1 deficiency is expected in the first half of 2026, with a potential market launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66730) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZLL34.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL7dDRbW:1","article_id":"2565846816","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565846816","pubTimestamp":1757336488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioMarin Pharmaceutical Inc. has announced new data from multiple studies highlighting its ongoing research in bone health. At the American Society for Bone and Mineral Research 2025 Annual Meeting in Seattle, BioMarin presented results from 14 studies, including those concerning VOXZOGO . The data demonstrated that treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children with achondroplasia and showed continued efficacy in children who received the medicine after the onset of puberty. Additionally, BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for ENPP1 deficiency. The initial pivotal data readout for the ENERGY 3 study in children with ENPP1 deficiency is expected in the first half of 2026, with a potential market launch in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BMRN":"拜玛林制药","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4566":"资本集团","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"BioMarin公布BMN 401治疗ENPP1缺乏症的有希望的初始数据，预计2027年上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9},"content_text":"BioMarin Unveils Promising Initial Data for BMN 401 in ENPP1 Deficiency, Eyes 2027 Launch\n    \n\n        BioMarin Pharmaceutical Inc. has announced new data from multiple studies highlighting its ongoing research in bone health. At the American Society for Bone and Mineral Research 2025 Annual Meeting in Seattle, BioMarin presented results from 14 studies, including those concerning VOXZOGO® (vosoritide). The data demonstrated that treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children with achondroplasia and showed continued efficacy in children who received the medicine after the onset of puberty. Additionally, BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for ENPP1 deficiency. The initial pivotal data readout for the ENERGY 3 study in children with ENPP1 deficiency is expected in the first half of 2026, with a potential market launch in 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66730) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}